Research Area: Cardiovascular Disease
Biological Activity:
Ciprofibrate is a peroxisome proliferator-activated receptor agonist. [1] It was reported that ciprofibrate decreased the levels of plasma triglycerides and total cholesterol as well as low-density lipoprotein cholesterol. Meanwhile, ciprofibrate elevated plasma levels of high-density lipoprotein cholesterol. The maximum concentration time of ciprofibrate is between one hour and 2.5 hours while the long half life (80 -100 h) permits daily dosing of the drug. In addition, the maximum plasma concentration is between 66 and 88 μg/mL after chronic administration of 100 mg/day of ciprofibrate. Ciprofibrate belongs to the second generation of fibric acid derivatives which used to treat patients with dyslipidaemias of various types. [2]